L DAmbrosio
Overview
Explore the profile of L DAmbrosio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1476
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Silva D, Centis R, DAmbrosio L, Visca D, Tiberi S, Akkerman O, et al.
Int J Tuberc Lung Dis
. 2024 Aug;
28(9):470-472.
PMID: 39188005
No abstract available.
2.
Migliori G, Bhatia V, DAmbrosio L, Raviglione M, Rijal S
IJTLD Open
. 2024 Jun;
1(1):7-10.
PMID: 38919415
No abstract available.
3.
van den Boom M, Bennani K, Migliori G, DAmbrosio L, Centis R, Parvez Sayed A, et al.
IJTLD Open
. 2024 Jun;
1(1):50-55.
PMID: 38919409
Background: In 2022, 11 of 22 Member States of the WHO Eastern Mediterranean Region (EMR) had an estimated TB incidence of <20 cases per 100,000 population. We assessed preparedness for...
4.
Rezaee M, Azizi N, Danaei B, Davari A, Nejadghaderi S, Sarmastzadeh T, et al.
Int J Tuberc Lung Dis
. 2024 Mar;
28(3):130-135.
PMID: 38454180
<sec id="st1"><title>INTRODUCTION</title>To determine the frequency of TB among patients with interstitial lung diseases (ILDs).</sec><sec id="st2"><title>METHODS</title>We performed a comprehensive search in the PubMed/Medline, EMBASE and Scopus databases up to 1 August...
5.
Oehadian A, Bastos M, Centis R, DAmbrosio L, Migliori G, Santoso P, et al.
Pulmonology
. 2023 Oct;
30(2):184-187.
PMID: 37783640
No abstract available.
6.
Visca D, Centis R, Pontali E, Zampogna E, Russell A, Migliori G, et al.
Int J Tuberc Lung Dis
. 2023 Sep;
27(10):729-741.
PMID: 37749839
The aim of these clinical standards is to provide guidance on 'best practice' care for the diagnosis, treatment and prevention of post-COVID-19 lung disease. A panel of international experts representing...
7.
Nasiri M, Silva D, Rommasi F, Zahmatkesh M, Tajabadi Z, Khelghati F, et al.
Pulmonology
. 2023 Sep;
31(1):2416801.
PMID: 37679219
Introduction And Objectives: Post-tuberculosis lung disease (PTLD), as other chronic respiratory disorders, may have infectious complications; some of them can be prevented with vaccinations. So far, no document has discussed...
8.
Silva D, Dos Santos A, Centis R, DAmbrosio L, Migliori G
Pulmonology
. 2023 Jun;
29(6):535-539.
PMID: 37349196
No abstract available.
9.
Nannini M, Rizzo A, Nigro M, Vincenzi B, Mazzocca A, Grignani G, et al.
ESMO Open
. 2021 Aug;
6(4):100222.
PMID: 34352702
Background: Despite its proven activity as third-line treatment in gastrointestinal stromal tumors (GIST), regorafenib can present a poor tolerability profile which often leads to treatment modifications and transient or permanent...
10.
Koirala S, Borisov S, Danila E, Mariandyshev A, Shrestha B, Lukhele N, et al.
Pulmonology
. 2021 Mar;
27(5):403-412.
PMID: 33753021
The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline...